10-Q: Veru Faces Going Concern Amid Promising Drug Trials

Veru Inc. reports significant net losses and a going concern warning despite positive Phase 2b clinical trial results for enobosarm and strategic pipeline advancements.

Summary

• Veru Inc. reported a net loss of $7.3 million for the three months ended June 30, 2025, an improvement from a $11.0 million loss in the same period of 2024.
• For the nine months ended June 30, 2025, the net loss was $24.2 million, compared to $29.3 million for the prior year period.
• Cash, cash equivalents, and restricted cash decreased to $15.0 million as of June 30, 2025, from $24.9 million at September 30, 2024.
• The company completed the sale of its FC2 business on December 30, 2024, for $18.0 million in cash, resulting in net proceeds of approximately $16.3 million and a loss on sale of $4.3 million.
• A gain on extinguishment of debt of $8.6 million was recognized in the nine months ended June 30, 2025, due to the termination of the Residual Royalty Agreement with a $4.2 million payment.
• Veru's Phase 2b QUALITY clinical trial for enobosarm met its primary endpoint, showing a statistically significant 100% relative reduction in lean mass loss (p<0.001) in patients receiving enobosarm 3mg + semaglutide.
• Enobosarm treatment also led to dose-dependent greater fat loss, with the 6mg dose showing a 42% greater relative fat loss (p=0.017) and the 3mg dose showing a 12% greater fat loss.
• The Phase 2b extension study demonstrated that enobosarm monotherapy significantly prevented the regain of both weight and fat mass after semaglutide discontinuation, with the 3mg group reducing body weight regained by 46%.
• A novel, patentable, modified release oral formulation for enobosarm completed its initial Phase 1 bioavailability clinical trial in July 2025, with an expected patent expiry of 2045.
• The company is exploring the clinical development of sabizabulin for atherosclerotic cardiovascular disease, having held a pre-IND meeting with the FDA's Division of Cardiology and Nephrology on December 26, 2024.
• Veru continues to face uncertainty regarding the collection of remaining payments from ONCO for the ENTADFI asset sale, with promissory notes extended multiple times and an additional $0.1 million loaned to ONCO on August 7, 2025.
• A 1-for-10 reverse stock split was effected on August 8, 2025, to help maintain Nasdaq listing compliance.

Sentiment

Score: 4

Explanation: While the clinical trial results for enobosarm are highly positive and represent significant scientific progress in a large market, the company's severe financial distress, including a 'going concern' warning, substantial cash burn, and explicit need for significant capital, heavily weighs down the overall sentiment. The ongoing legal disputes and uncertainty around ONCO payments further contribute to a cautious outlook, despite the promising pipeline.

Positives

• Enobosarm's Phase 2b QUALITY clinical trial met its primary endpoint, demonstrating a statistically significant 100% relative reduction in lean mass loss (p<0.001) in sarcopenic obese or overweight elderly patients receiving semaglutide.
• Enobosarm treatment resulted in dose-dependent greater fat loss, with the 6mg dose showing a 42% greater relative fat loss (p=0.017) and the 3mg dose showing a 12% greater fat loss compared to placebo + semaglutide.
• The Phase 2b extension study showed enobosarm monotherapy significantly prevented weight and fat mass regain after semaglutide discontinuation, with the 3mg group reducing body weight regained by 46%.
• Enobosarm's combination with semaglutide showed a positive safety profile, with no increases in gastrointestinal side effects, no drug-induced liver injury, no increases in obstructive sleep apnea, no increases in prostate specific antigen in men, no masculinization in women, and no suicidal ideation.
• The 3mg enobosarm + semaglutide combination had the added benefit of fewer gastrointestinal side effects (diarrhea, nausea, and gastroesophageal reflux disease) compared to semaglutide alone.
• A novel, patentable, modified release oral formulation for enobosarm completed its initial Phase 1 bioavailability clinical trial in July 2025, with an expected patent expiry of 2045, potentially extending intellectual property protection.
• The FDA agreed that there remains an unmet medical need for sabizabulin in atherosclerotic cardiovascular disease during a pre-IND meeting.
• The sale of the FC2 business generated net proceeds of approximately $16.3 million and resulted in an $8.6 million gain on extinguishment of debt by terminating the Residual Royalty Agreement.

Negatives

• The company incurred a net loss of $7.3 million for the three months ended June 30, 2025, and $24.2 million for the nine months ended June 30, 2025.
• Cash, cash equivalents, and restricted cash significantly decreased to $15.0 million at June 30, 2025, from $24.9 million at September 30, 2024.
• The company has a history of net losses and currently has no commercial revenue, expecting to incur significant operating losses for the foreseeable future.
• The independent registered public accounting firm included an explanatory paragraph relating to the company's ability to continue as a going concern.
• The company will need to raise substantial additional capital to fund its drug development and commercialization efforts, which may not be available on favorable terms or at all, potentially leading to significant dilution.
• There is uncertainty regarding the receipt of additional payments from ONCO for the ENTADFI assets, with the company believing the probability of receiving milestone payments is remote and having no security interest in ONCO's assets.
• The company is subject to significant payment obligations of $8.3 million to a supplier for sabizabulin commercialization efforts, with $2.5 million due by December 31, 2025, potentially requiring additional capital if ONCO payments are not received.
• Ongoing legal proceedings, including multiple shareholder class actions and a new lawsuit from the FC2 business purchaser, could result in substantial legal fees, fines, penalties, or damages, and divert management's attention.
• The company recorded a $4.3 million loss on the sale of the FC2 business.

Risks

• Inability to obtain sufficient financing on acceptable terms, potentially leading to cessation of operations, asset sales, or significant dilution of stockholders' equity.
• Uncertainty regarding the receipt of additional payments from Onconetix, Inc. (ONCO) in connection with the sale of ENTADFI assets, and the risk of future default by ONCO.
• Potential delays in the timing of and results from clinical trials and studies, including patient recruitment and regulatory approvals.
• Risk that clinical trial results, including early data, may not be replicated in additional trials or clinical practice, or may not support marketing approval.
• Reliance on contract research organizations (CROs) and third-party manufacturers, with risks of delays, quality issues, or non-compliance.
• Exposure to product liability claims from clinical testing and future commercialization of drug candidates.
• Ongoing legal proceedings (Shareholder Litigation, Clear Future Lawsuit) that could result in substantial legal fees, fines, penalties, or damages.
• Significant payment obligations to a supplier ($8.3 million settlement) that could strain liquidity if not met.
• Competition from major pharmaceutical companies and other entities in the highly competitive pharmaceutical industry, especially for enobosarm in metabolic diseases.
• Inability to protect intellectual property rights, including patents expiring, invalidation, or infringement by third parties.
• Highly concentrated ownership of common stock, limiting the ability of other shareholders to influence corporate matters.
• Risk of delisting from the Nasdaq Capital Market if the minimum bid price requirement is not maintained.
• Potential for future material weaknesses or other deficiencies in internal control over financial reporting, despite remediation of prior weaknesses.
• Uncertainties in the interpretation and application of tax rules, potentially impacting deferred tax assets and effective tax rate.
• Limitations on the ability to use net operating loss carryforwards and certain other tax attributes due to corporate ownership changes.

Future Outlook

The company plans to propose a Phase 3 clinical program for enobosarm, similar to the positive Phase 2b QUALITY clinical trial, to the FDA. This program will evaluate enobosarm's effect on physical function, total lean mass, total fat mass, HOMA-IR, and hemoglobin A1c in sarcopenic obese or overweight elderly patients receiving GLP-1 RAs like WEGOVY or Zepbound. Longer-term benefits will be measured up to 68 weeks. For sabizabulin, the company intends to submit an IND in Q1 2026 for a Phase 2 study to measure high sensitivity C-reactive protein in stable coronary artery disease patients. The company expects to continue investing significant resources in research and development and will need substantial additional capital to fund its operations and advance its drug candidates.

Management Comments

• We believe there is an urgent unmet need for a drug that can ameliorate the muscle wasting effects of currently approved GLP-1 RA therapies and also allow for greater loss of fat mass in at-risk sarcopenic obese and overweight older patients.
• We believe the clinical data we own that was generated from third-party clinical trials of enobosarm in both older patients and in patients with initial and ongoing muscle wasting, provide strong clinical rationale for the co-administration of enobosarm and a GLP-1 RA.
• The Phase 2b QUALITY study is the first human study to report the effects of a muscle preservation drug candidate on body composition in older patients who have obesity or are overweight and receiving a GLP-1 receptor agonist.
• Enobosarm represents a novel drug that improves GLP-1 RA therapy resulting in tissue selective quality weight reduction, that is, enobosarm + semaglutide improved changes in body composition which resulted in more selective and greater loss of adiposity (fat mass) than in subjects receiving placebo + semaglutide alone.
• The Phase 2b QUALITY and Maintenance Extension clinical trial confirmed that preserving lean mass with enobosarm plus semaglutide led to greater fat loss during the active weight loss period, and after semaglutide was discontinued, enobosarm monotherapy significantly prevented the regain of both weight and fat mass during the maintenance period.
• We believe there is compelling scientific evidence and rationale to evaluate sabizabulin as a treatment for the inflammation associated with atherosclerotic cardiovascular disease.
• Colchicine may be first-in-class and the first FDA approved treatment for this significant indication to treat atherosclerotic inflammation, but unfortunately colchicine has significant safety concerns that may limit its expected widespread use and therefore does not address the current unmet medical need of atherosclerotic inflammation.
• Because sabizabulin has a different chemical structure than colchicine, it is not a substrate for CYP3A4 and P-glycoprotein potentially eliminating drug-drug interactions concerns associated with colchicine.

Industry Context

The company's focus on enobosarm for sarcopenic obesity in GLP-1 RA patients positions it in a rapidly growing and highly competitive cardiometabolic market, addressing a key side effect (muscle loss) of popular weight-loss drugs like Wegovy and Zepbound. This strategy aims to differentiate its offering by improving the 'quality' of weight loss. The pivot of sabizabulin to atherosclerotic cardiovascular disease inflammation aligns with emerging understanding of inflammation's role in heart disease, following the FDA's approval of colchicine for this indication. This move seeks to capitalize on a large market with a potentially safer alternative to existing treatments, given sabizabulin's favorable drug-drug interaction profile compared to colchicine.

Comparison to Industry Standards

• Enobosarm's Phase 2b QUALITY study demonstrated a 100% relative reduction in lean mass loss, a significant improvement compared to the 20-50% lean mass loss typically observed in third-party clinical trials evaluating currently approved GLP-1 RAs in obese patients.
• The 3mg enobosarm + semaglutide group showed a 59.8% relative reduction in patients experiencing a clinically significant decline in stair climb power, indicating a substantial improvement in physical function preservation compared to semaglutide alone, addressing a key concern with GLP-1 RA therapies.
• Sabizabulin's mechanism of action is similar to colchicine, which has shown significant cardiovascular risk reduction (e.g., 31% reduction in MACE in COLCOT, LoDoCo, LoDoCo-2 trials). Sabizabulin's potential to avoid CYP3A4 and P-glycoprotein interactions could offer a safer profile compared to colchicine, which has known serious safety concerns and drug-drug interactions with commonly used cardiovascular drugs like statins.

Corporate Governance

Legal Proceedings

• Ewing v. Veru Inc., et al. (Case No. 1:22-cv-23960): Putative securities class action alleging false statements about sabizabulin for COVID-19, seeking monetary damages.
• Maglia v. Steiner et al. (Case No. 2023-019406-CA-01): Derivative action asserting claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment.
• Franchi v. Steiner et al. (Case No. 2:23-CV-01164): Derivative action asserting claims for breach of fiduciary duty and unjust enrichment, consolidated with Renbarger Lawsuit.
• Renbarger v. Steiner et al. (Case No. 2:23-CV-01291): Derivative action asserting claims for breach of fiduciary duty, aiding and abetting, gross mismanagement, waste of corporate assets, and unjust enrichment, consolidated with Franchi Lawsuit.
• Alshourbagy v. Steiner et al. (Case No. 1:23-cv-23846): Derivative action asserting claims for breach of fiduciary duty and contribution.
• Ovadias v. Steiner et al. (Case No. 3:24-cv-00676): Derivative action asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution.
• Clear Future, Inc. v. Veru Inc. (Case No. N25C-08-066 EMD): Lawsuit filed by the FC2 business purchaser alleging breach of representations and warranties and fraud related to a customer relationship, seeking indemnification for a pre-closing tax liability of approximately $137,000.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity capital raises due to the company's substantial funding needs and low stock price.
• Shareholders are exposed to high volatility in stock price due to the company's financial condition, clinical trial outcomes, and ongoing legal proceedings.
• Shareholders will not receive cash dividends in the foreseeable future, with capital appreciation being the sole source of gain.
• Employees are impacted by share-based compensation plans, which are a significant component of compensation.
• Customers (future patients) could benefit from the successful development and commercialization of enobosarm and sabizabulin, addressing unmet medical needs in obesity and cardiovascular disease.
• Suppliers, particularly the one involved in the $8.3 million dispute settlement, are impacted by the company's ability to meet its payment obligations.
• Creditors, especially those holding the ONCO promissory notes, face uncertainty regarding repayment due to ONCO's defaults and the company's unsecured creditor status.
• Regulatory bodies are actively engaged with the company through IND meetings and ongoing compliance requirements, impacting the pace and direction of drug development.

Next Steps

• Propose a Phase 3 clinical program for enobosarm to the FDA, similar to the Phase 2b QUALITY clinical trial design.
• Initiate a Phase 3 clinical trial for enobosarm, which will be a double-blind, placebo-controlled study in patients 60 years of age and older with obesity or overweight, receiving GLP-1 RA.
• Continue to measure total lean mass, total body weight, stair climb, total fat mass, bone mineral density, HOMA-IR, and hemoglobin A1c up to 68 weeks in the enobosarm program to capture longer-term benefits.
• Submit an Investigational New Drug (IND) application for sabizabulin as a treatment to slow progression or promote regression of atherosclerotic disease in Q1 2026.
• Conduct a Phase 2, double-blind, placebo-controlled, efficacy and safety study of oral sabizabulin to measure high sensitivity C-reactive protein in patients with stable coronary artery disease.
• Resolve the dispute with Clear Future, Inc. regarding the FC2 business sale working capital adjustment through binding resolution by an accounting firm.
• Address the Clear Future Lawsuit filed on August 5, 2025, alleging breach of representations and warranties and fraud.
• Continue to pursue payment for accounts receivable from The Pill Club bankruptcy estate, though recovery is unlikely.
• Manage and make payments for the $8.3 million settlement with a supplier related to sabizabulin commercialization efforts.
• Seek additional capital through public or private equity offerings, debt financing, and/or other capital sources to fund operations and drug development.

Key Dates

Recommendation

While the positive Phase 2b clinical data for enobosarm is a significant scientific achievement and addresses a large, unmet medical need in the rapidly growing GLP-1 RA market, the company's severe financial challenges, including an explicit 'going concern' warning, substantial negative cash flow from operations, and the stated need for significant additional capital, create a high-risk investment profile. The ongoing legal proceedings and uncertainty surrounding the ONCO payments further add to the financial instability. For existing investors, holding may be justified given the potential long-term upside of the clinical pipeline, but for new investors, the immediate financial risks are substantial, making a 'buy' recommendation premature without clearer paths to sustainable funding and profitability.

Keywords

Biopharmaceutical, Drug Development, Clinical Trials, Enobosarm, Sabizabulin, GLP-1 RA, Obesity, Sarcopenia, Cardiometabolic Disease, Atherosclerosis, SEC Filing, 10-Q, Going Concern, Capital Raise, Asset Sale, Debt Extinguishment, Intellectual Property, Legal Proceedings, Nasdaq